The lotion, intended to treat skin conditions like eczema and psoriasis, represents Teligent’s sixth approval from its internally developed portfolio of topical generic drug products, according to a news release.
The company plans to launch the lotion in the first quarter of 2017.
More articles on supply chain:
Addiction centers pay more than $700k to resolve allegations of improper prescribing
Court orders contracted pilots for Amazon, DHL to return to work after strike
DEA bans furanyl fentanyl
